Octreotide (Sandostatin): Somatostatin Analog for Acromegaly and Neuroendocrine Tumors — Research Overview

Octreotide (brand name Sandostatin; long-acting release formulation Sandostatin LAR Depot) is a synthetic cyclic octapeptide that mimics the pharmacological actions of the natural hormone somatostatin. It was first described by Lamberts and colleagues in landmark 1985 and 1988 papers in the New England Journal of Medicine and has since become a cornerstone of medical management for acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). As the first long-acting synthetic somatostatin analog to reach clinical use, octreotide transformed the treatment landscape for conditions that previously offered few pharmacological options.

What Is Octreotide?

Octreotide (SMS 201-995) is an eight-amino acid cyclic peptide that was designed to retain the four-amino acid pharmacophore core of somatostatin while being resistant to rapid proteolytic degradation. Native somatostatin has a plasma half-life of only 1–3 minutes, making it impractical for clinical administration. By cyclizing the peptide and incorporating D-phenylalanine and L-threonine residues, researchers created a molecule with a plasma half-life of approximately 1.5–2 hours that retains high affinity for somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5), the subtypes most relevant to growth hormone and peptide hormone suppression.

Two principal formulations are in clinical use: Sandostatin Injection (immediate-release, for subcutaneous or intravenous administration, dosed 2–3 times daily) and Sandostatin LAR Depot (a long-acting release microsphere formulation for once-monthly intramuscular injection, appropriate for stable patients).

Mechanism of Action

Octreotide exerts its effects through binding to somatostatin receptors (SSTRs), a family of five G-protein-coupled receptors (SSTR1–5) expressed on neuroendocrine cells, pituitary cells, and many tumor types. The drug has highest affinity for SSTR2 and SSTR5. Receptor binding inhibits adenylyl cyclase and reduces intracellular cAMP, leading to suppression of multiple secretory processes.

In the pituitary, SSTR2 and SSTR5 activation suppresses growth hormone (GH) secretion. In the gastrointestinal tract, octreotide inhibits secretion of serotonin, gastrin, glucagon, insulin, secretin, motilin, vasoactive intestinal peptide (VIP), and pancreatic polypeptide. It also reduces pancreatic exocrine secretion, inhibits gallbladder contraction, and slows intestinal motility. This broad antisecretory profile underlies both its utility in acromegaly and in the symptomatic control of functional NETs.

For NETs, beyond symptom control, evidence from the PROMID and CLARINET trials (primarily using octreotide LAR and lanreotide, respectively) established antiproliferative activity of first-generation somatostatin analogs at the SSTR level, resulting in progression-free survival benefit independent of hormone secretory status.

What the Research Shows

The foundational clinical evidence came from Lamberts et al. (NEJM, 1985), reporting that subcutaneous SMS 201-995 rapidly reduced mean plasma GH concentrations from 57 ± 18 μg/L to 7.5 ± 2 μg/L in four acromegalic patients, with near-normalization of IGF-1. This proof-of-concept work established the drug class. Subsequent large open-label and Phase III trials in acromegaly confirmed that octreotide SC injection (100–300 μg 3×/day) normalized GH to < 2.5 ng/mL in approximately 50% of patients and normalized IGF-1 in 50–60%. Octreotide LAR 20–30 mg IM monthly produced similar rates of biochemical control.

In metastatic carcinoid tumors, octreotide SC significantly reduced flushing episodes and diarrhea in the majority of patients in early controlled studies. The PROMID trial (Rinke et al., NEJM 2009) randomized 85 patients with well-differentiated midgut NETs to octreotide LAR 30 mg or placebo, demonstrating a statistically significant increase in median time to tumor progression (14.3 months vs 6.0 months, hazard ratio 0.34, P = 0.000072). This landmark result established octreotide LAR as standard of care for inoperable, well-differentiated midgut NETs.

For VIPomas (vasoactive intestinal peptide-secreting tumors causing profuse watery diarrhea), octreotide reduces VIP levels and controls diarrhea in the majority of patients. The FDA label for Sandostatin Injection and LAR includes this indication. Current comparative data suggest octreotide LAR and lanreotide autogel achieve similar rates of biochemical control and symptom suppression in acromegaly, though direct head-to-head trials are limited.

Pharmacokinetics

Octreotide injection (immediate-release) is rapidly absorbed after subcutaneous administration. Peak plasma concentrations are reached within 30–60 minutes (Tmax). The terminal elimination half-life is approximately 1.5 hours. Volume of distribution is approximately 13.6 L. Plasma protein binding is 65%, primarily to lipoprotein and albumin. Approximately 32% of dose is excreted unchanged in urine.

Sandostatin LAR Depot provides biphasic release: an initial burst phase followed by a plateau phase from days 14–42. After the third monthly injection, steady-state plasma concentrations are achieved. Plasma concentrations of octreotide are dose-proportional across the 10–30 mg dose range. In patients with renal impairment, total body clearance is reduced and the half-life extended; dose adjustment may be required in severe impairment. Hepatic impairment in patients with liver cirrhosis (but not fatty liver disease) also prolongs half-life.

Approved Indications and Clinical Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

For acromegaly: The FDA label for Sandostatin Injection specifies 50 mcg SC three times daily as the initial dose, titrated to clinical response up to 100–500 mcg TID. For Sandostatin LAR Depot in patients already responding to SC octreotide, the label specifies initiation at 20 mg IM every 4 weeks for 3 months, with subsequent titration to 10–30 mg based on GH and IGF-1 levels.

For carcinoid tumors and VIPomas: The Sandostatin Injection label specifies an initial dose of 100–600 mcg SC daily in 2–4 divided doses. The Sandostatin LAR Depot label specifies 20 mg IM every 4 weeks for 2 months, adjusted based on response, up to 30 mg. All dose ranges cited come from the FDA-approved prescribing information; individual patient dosing is determined by the treating clinician.

Storage and Handling

Sandostatin Injection ampules and multidose vials should be stored refrigerated at 2–8°C (36–46°F) and protected from light. Ampules may be kept at room temperature (up to 25°C) for up to 14 days when protected from light. Sandostatin LAR Depot kits must be refrigerated and brought to room temperature prior to administration; the microsphere powder should be prepared as directed and administered immediately after reconstitution. Reconstituted LAR suspension must not be stored; discard any unused portion.

What Octreotide Is NOT

Octreotide is sometimes conflated with lanreotide (Somatuline Depot), another first-generation somatostatin analog. While both bind SSTR2 and SSTR5 and share clinical indications, they are chemically distinct peptides with different depot formulation technologies (PLGA microspheres vs. deep subcutaneous aqueous gel) and are not interchangeable without clinical re-evaluation.

Octreotide is also not a growth hormone secretagogue (contrast with sermorelin, CJC-1295, or ipamorelin), and it does not increase GH levels. It suppresses GH, making it the pharmacological opposite of GH-releasing peptides in the research peptide space. Octreotide should not be confused with pasireotide (Signifor), a second-generation multi-receptor somatostatin analog with different receptor binding profile, used for Cushing's disease and acromegaly refractory to first-line SSAs.

References

1. Lamberts SW, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 1985;313(25):1576–1580.

2. Rinke A, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663.

3. U.S. FDA. Sandostatin Injection (octreotide acetate) Prescribing Information. NDA 019667. Updated 2023.

4. U.S. FDA. Sandostatin LAR Depot (octreotide acetate for injectable suspension) Prescribing Information. NDA 021008. Updated 2024.

5. Gadelha MR, et al. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer. 2016;23(12):R551–R557. PMID 27697899.